PolyPeptide Group AG (XSWX:PPGN) ROCE % : -7.51% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. PolyPeptide Group AG's annualized ROCE % for the quarter that ended in Dec. 2023 was -7.51%.

PolyPeptide Group AG ROCE % Historical Data

The historical data trend for PolyPeptide Group AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG ROCE % Chart

PolyPeptide Group AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

14.11

15.65

16.16

1.94

-10.37

PolyPeptide Group AG Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					13.21	6.28	-2.36	-14.88	-7.51

PolyPeptide Group AG ROCE % Calculation

PolyPeptide Group AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-49.625	/	( ( (568.219 - 94.79)	+	(649.862 - 166.406) )	/ 2 )
	=	-49.625	/	( (473.429	+	483.456)	/ 2 )
	=	-49.625	/	478.4425
	=	-10.37 %

PolyPeptide Group AG's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-34.284	/	( ( (574.698 - 145.171)	+	(649.862 - 166.406) )	/ 2 )
	=	-34.284	/	( ( 429.527	+	483.456 )	/ 2 )
	=	-34.284	/	456.4915
	=	-7.51 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

PolyPeptide Group AG (XSWX:PPGN) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

PolyPeptide Group AG ROCE % Related Terms

Thank you for viewing the detailed overview of PolyPeptide Group AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

PolyPeptide Group AG (XSWX:PPGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PPGNz:UK

Address

Neuhofstrasse 24, Baar, Zug, CHE, 6340

Website

https://www.polypeptide.com

PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines